Vanguard Asset Management
MBX

Vanguard Asset Management’s MBX Biosciences MBX Stock Holding History

Vanguard Asset Management’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$814K Hold
14,752
– – ﹤0.01% 1988
2026
Q1 		$440K Buy
+14,752
New +$502K ﹤0.01% 2153

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AWA
Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Asset Management's MBX Position: Q2 2026 in Review

Vanguard Asset Management held its MBX Biosciences (MBX) position steady in Q2 2026 at 14,752 shares worth $814K. The position accounts for ﹤0.01% of the portfolio, ranked #1988.

Vanguard Asset Management first reported a position in MBX in Q1 2026 and has held it in 2 quarters since. 158 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • Vanguard Asset Management held 14,752 shares of MBX Biosciences worth $814K as of Q2 2026.
  • Vanguard Asset Management left its MBX Biosciences share count unchanged in Q2 2026.
  • MBX Biosciences made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #1988 holding.
  • Vanguard Asset Management first reported a position in MBX Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 158 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.